Vesugen side effects and risks

Reported side effects

• Allergic or injection-related reactions: No compound specific rate is established. These are general risks of unapproved peptide products., serious. Stop use and seek care for a spreading reaction or signs of infection. (source)
• Other short- and long-term effects: No reliable adverse event denominator is available., moderate. Report new symptoms and the exact product, dose, route and timing. (source)
• Prooxidant and blood-cell-marker changes: One 32 person report noted increased oxidation signals and lower circulating CD34+ cells; no rates or clinical harms were quantified., moderate. Discuss unexplained bruising, infection or fatigue and whether a blood count is needed. (source)

Stop and get help if

• Trouble breathing, throat swelling, widespread hives or collapse: Call emergency services now; these may be signs of anaphylaxis.
• Fever with confusion, rapid breathing or a very painful spreading injection-site infection: Get emergency care now; severe infection can progress quickly.
• Sudden face droop, one-sided weakness, speech trouble or vision loss: Call emergency services now, even if symptoms improve. These can be stroke signs.
• Chest pressure or pain with shortness of breath, sweating or lightheadedness: Call emergency services now for possible heart attack.

Who should avoid it

• pregnant: Precaution: no reliable pregnancy safety data for this peptide.
• breastfeeding: Precaution: transfer into milk and infant effects are unknown.
• tryingToConceive: Precaution: fertility and early-pregnancy effects are unknown.
• under18: Precaution: no reliable pediatric safety evidence was located.
• kidneyDisease: Clearance and dose adjustment in kidney disease are unknown.
• liverDisease: No liver-disease dose or safety study was located.
• testedAthlete: The 2026 S0 rule is expected to prohibit this unapproved substance at all times.
• activeCancer: Precaution: KED alters cell-growth and IGF1 signals in culture. Effects on tumor growth in people are unknown.
• cancerHistory: Small post-cancer dental reports do not establish recurrence safety.
• bleedingDisorder: Patent claims include changes in clotting tests; effects on bleeding and thrombosis are unconfirmed.
• heartCondition: Small vascular reports do not show protection from heart attack or stroke.

Interactions

• Anticoagulants and antiplatelet drugs: Interaction unstudied. Patent clotting-test changes make combined use a precaution, not a proven interaction.
• Cyclophosphamide: KED reduced cyclophosphamide growth suppression in rat tissue culture. Whether this affects cancer therapy is unknown.
• Other experimental bioregulators and recovery peptides: Small reports and forum stacks cannot establish interaction safety or attribute effects to one peptide.

Product quality risks

• No independent published market-testing study specific to this peptide was located.
• General peptide warnings describe wrong strength, wrong ingredients and microbial contamination.
• An online semaglutide study found low purity and endotoxin. This does not measure contamination in this peptide.